ACLARION, INC. (ACON) Spending and interest coverage
- R&D / revenue · 12 months: Value 1405.84%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 152.71%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 1405.84% | Research and development expense / revenue. Period ending 2026-06-30. $1.18M ÷ $83.77K × 100 ≈ 1405.84% |
| Stock-based compensation / revenue · 12 months | 152.71% | Share-based compensation / revenue. Period ending 2026-06-30. $127.92K ÷ $83.77K × 100 ≈ 152.71% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 1.18M USD | Research and Development Expense |
| Revenue | 83.77K USD | |
| Stock-based compensation | 127.92K USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -9.71M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.18M | $83.77K | $127.92K | $-9.71M | (m) | 1405.84% | 152.71% | (m) | (m) |
| 2026-03-31 | $1.15M | $77.88K | $54.16K | $-8.55M | (m) | 1477.95% | 69.55% | (m) | (m) |
| 2025-12-31 | $1.03M | $75.73K | $105.37K | $-7.05M | (m) | 1365.10% | 139.14% | (m) | (m) |
| 2025-09-30 | $1.02M | $67.48K | $157.62K | $-6.87M | (m) | 1515.17% | 233.57% | (m) | (m) |
| 2025-06-30 | $916.25K | $62.95K | $215.58K | $-6.33M | (m) | 1455.56% | 342.47% | (m) | (m) |
| 2025-03-31 | $847.91K | $54.60K | $257.52K | $-5.73M | (m) | 1552.93% | 471.65% | (m) | (m) |
| 2024-12-31 | $888.77K | $45.72K | $287.45K | $-5.51M | $64.08K | 1943.76% | 628.67% | -86.03× | Reported |
| 2024-09-30 | $857.62K | $49.29K | $330.37K | $-4.83M | (m) | 1739.98% | 670.27% | (m) | (m) |
| 2024-06-30 | $860.07K | $53.95K | $392.97K | $-4.70M | (m) | 1594.29% | 728.44% | (m) | (m) |
| 2024-03-31 | $907.98K | $60.05K | $459.30K | $-4.97M | $942.73K | 1512.09% | 764.88% | -5.27× | Reported |
| 2023-12-31 | $873.34K | $75.40K | $456.00K | $-4.88M | $608.29K | 1158.21% | 604.74% | -8.02× | Reported |
| 2023-09-30 | $871.65K | $84.13K | $492.30K | $-4.69M | $216.92K | 1036.12% | 585.19% | -21.63× | Reported |
| 2023-06-30 | $964.37K | $83.28K | $681.19K | $-5.16M | $52.66K | 1157.93% | 817.92% | -98.05× | Reported |
| 2023-03-31 | $1.07M | $76.89K | $1.25M | $-5.97M | $1.35M | 1388.50% | 1620.63% | -4.43× | Reported |
| 2022-12-31 | $1.09M | $60.44K | $1.19M | $-6.10M | $1.51M | 1801.30% | 1963.24% | -4.05× | Reported |
| 2022-09-30 | (m) | (m) | $980.47K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | $41.51K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $23.12K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $177.49K | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |